[
    "{\"step_by_step_thinking\": \"Based on the provided documents, ibudilast has been studied as a potential treatment for multiple sclerosis (MS). Document [0] states that ibudilast has been approved for \"fast track\" development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive MS. Document [1] mentions that ibudilast has anti-inflammatory and neuroprotective properties and is currently being studied in progressive MS. Document [2] reports that ibudilast showed a reduction in brain volume loss and disability progression in relapsing forms of MS. Document [6] also mentions that ibudilast treatment was associated with a reduction in gray matter atrophy. Document [7] states that ibudilast was associated with slower progression of brain atrophy in progressive MS. However, it is important to note that not all studies showed a significant reduction in disease activity or lesion rate. Based on the available evidence, it can be concluded that ibudilast has shown some potential benefits in the treatment of MS, particularly in terms of neuroprotection and reducing brain atrophy. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]